Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice
Atherosclerosis Supplements, Volume 15, No. 1, Year 2014
Notification
URL copied to clipboard!
Description
Reducing low-density lipoprotein cholesterol (LDL-C) levels using statins is associated with significant reductions in cardiovascular (CV) events in a wide range of patient populations. Although statins are generally considered to be safe, recent studies suggest they are associated with an increased risk of developing Type 2 diabetes (T2D). This led the US Food and Drug Administration (FDA) to change their labelling requirements for statins to include a warning about the possibility of increased blood sugar and HbA1c levels and the European Medicines Agency (EMA) to issue guidance on a small increased risk of T2D with the statin class. This review examines the evidence leading to these claims and provides practical guidance for primary care physicians on the use of statins in people with or at risk of developing T2D. Overall, evidence suggests that the benefits of statins for the reduction of CV risk far outweigh the risk of developing T2D, especially in individuals with higher CV risk. To reduce the risk of developing T2D, physicians should assess all patients for T2D risk prior to starting statin therapy, educate patients about their risks, and encourage risk-reduction through lifestyle changes. Whether some statins are more diabetogenic than others requires further study. Statin-treated patients at high risk of developing T2D should regularly be monitored for changes in blood glucose or HbA1c levels, and the risk of conversion from pre-diabetes to T2D should be reduced by intensifying lifestyle changes. Should a patient develop T2D during statin treatment, physicians should continue with statin therapy and manage T2D in accordance with relevant national guidelines. © 2014.
Authors & Co-Authors
Sattar, Naveed A.
United Kingdom, Glasgow
Glasgow Cardiovascular Research Centre
Ginsberg, Henry N.
United States, New York
Vagelos College of Physicians and Surgeons
Ray, Kausik Kumar
United Kingdom, London
St George’s, University of London
Chapman, John
France, Paris
Hôpital Universitaire Pitié Salpêtrière
Arca, Marcello
Italy, Rome
Sapienza Università Di Roma
Averna, Maurizio
Italy, Palermo
Università Degli Studi Di Palermo
Betteridge, D. John
United Kingdom, London
University College London
Bhatnagar, Deepak
United Kingdom, Oldham
The Royal Oldham Hospital
Bilianou, Helen I.
Greece, Piraeus
Tzanion General Hospital
Carmena, Rafael
Spain, Valencia
Universitat de València
Ceska, R. C.
Czech Republic, Prague
Všeobecná Fakultní Nemocnice V Praze
Corsini, Alberto
Italy, Milan
Università Degli Studi Di Milano
Erbel, Raimund D.
Germany, Duisburg
Universität Duisburg-essen
Flynn, Paul D.
United Kingdom, Cambridge
Addenbrooke's Hospital
Garcia-Moll, Xavier
Spain, Barcelona
Hospital de la Santa Creu I Sant Pau
Gumprecht, Janusz
Poland, Katowice
Slaski Uniwersytet Medyczny w Katowicach
Ishibashi, Shun
Japan, Kawachi District
Jichi Medical University
Jambart, Sélim
Lebanon, Beirut
Faculté de Médecine
Kastelein, Johannes Jacob Pieter
Netherlands, Amsterdam
Universiteit Van Amsterdam
Maher, Vincent M.G.
Ireland, Dublin
Tallaght University Hospital
da Silva, Pedro Marqués
Portugal, Lisbon
Santa Marta's Hospital
Masana, Lluis L.
Spain, Tarragona
Universitat Rovira I Virgili
Odawara, Masato
Japan, Tokyo
Tokyo Medical University
Pedersen, Terje R.
Norway, Oslo
Ulleval University Hospital
Rotella, Carlo Maria
Italy, Florence
Università Degli Studi Di Firenze, Facoltà Di Medicina e Chirurgia
Salti, Ibrahim S.
Lebanon, Beirut
American University of Beirut
Teramoto, Tamio
Japan, Tokyo
Teikyo University
Tokgözoǧlu, Sadberk Lâle
Turkey, Ankara
Hacettepe Üniversitesi
Tóth, Peter Paul
United States, Chicago
University of Illinois College of Medicine
Valensi, Paul Elie
France, Villetaneuse
University Sorbonne Paris Nord
Vergès, Bruno L.
France, Dijon
Centre Hospitalier Universitaire Dijon Bourgogne
Statistics
Citations: 31
Authors: 31
Affiliations: 31
Identifiers
Doi:
10.1016/j.atherosclerosissup.2014.04.001
ISSN:
15675688
Research Areas
Food Security
Health System And Policy
Noncommunicable Diseases